South Korea Cancer Drug Market Overview, 2031

The adoption of advanced cancer drugs in South Korea is influenced by several regulatory, financial, and operational challenges despite the country’s highly advanced healthcare system. One of the primary barriers lies in the drug approval and reimbursement process managed by the Ministry of Food and Drug Safety (MFDS) and the Health Insurance Review and Assessment Service (HIRA). While innovative oncology drugs may receive regulatory approval relatively quickly, reimbursement decisions under the National Health Insurance (NHI) system often require detailed cost-effectiveness evaluations and pricing negotiations. These assessments can delay widespread adoption, particularly for high-cost targeted therapies and immunotherapies. Budget constraints within the national health insurance framework also encourage careful evaluation of new treatments to ensure sustainability of healthcare spending. Another challenge involves the need for specialized infrastructure and expertise required for precision oncology. Advanced therapies often require molecular diagnostic testing, genomic sequencing, and highly trained oncology professionals capable of managing complex treatment regimens. Although major hospitals in metropolitan areas such as Seoul possess strong diagnostic capabilities and specialized oncology units, smaller regional hospitals may face limitations in implementing advanced therapies due to resource constraints. Compliance requirements, pharmacovigilance obligations, and strict clinical guidelines further add operational complexity when introducing new oncology treatments. Additionally, integrating innovative therapies into existing hospital workflows and treatment protocols requires training programs and coordination among multidisciplinary teams. These barriers collectively create a controlled adoption environment in which new cancer drugs are typically introduced first in leading academic medical centers and specialized cancer institutes before gradually expanding to broader hospital networks across the country.

According to the research report, "South Korea Cancer Drug Market Outlook, 2031," published by Bonafide Research, the South Korea Cancer Drug market was valued at more than USD 2.83 Billion in 2025. Cancer drug adoption in South Korea accelerates when strong clinical evidence aligns with reimbursement approval under the National Health Insurance system and the capabilities of leading medical institutions. Once oncology drugs receive positive reimbursement decisions from HIRA, patient access expands rapidly due to the country’s universal healthcare coverage. Major tertiary hospitals and university medical centers play a central role in the early adoption of innovative therapies because they possess advanced molecular diagnostic laboratories, multidisciplinary tumor boards, and highly trained oncology specialists. South Korea also has a strong clinical research ecosystem, with many hospitals actively participating in international oncology trials that provide early access to cutting-edge treatments. Government initiatives promoting biotechnology innovation and precision medicine further support the development and adoption of targeted therapies and immunotherapies. The integration of genomic testing into routine oncology practice has increased the use of biomarker-driven treatments, particularly for cancers such as lung, gastric, and breast cancer. Collaboration between academic hospitals, pharmaceutical companies, and biotechnology firms contributes to the rapid dissemination of new treatment approaches. When reimbursement coverage, clinical expertise, and diagnostic infrastructure align, the adoption of innovative cancer therapies accelerates significantly. This interaction between policy support, technological capability, and research-driven healthcare institutions creates an environment where advanced oncology treatments can be introduced efficiently while maintaining careful oversight of healthcare costs and clinical outcomes.

Cancer treatment in South Korea includes a diverse range of therapeutic options such as chemotherapy, targeted therapies, immunotherapies, hormonal treatments, and emerging combination regimens. Chemotherapy continues to serve as a fundamental treatment modality for several cancers including gastric, colorectal, lung, and breast cancer. It remains widely used across hospitals due to established treatment protocols and relatively lower costs compared with newer therapies. However, the oncology landscape has gradually shifted toward targeted therapies designed to interfere with specific molecular mechanisms responsible for tumor growth. Drugs such as tyrosine kinase inhibitors and monoclonal antibodies are increasingly prescribed when biomarker testing identifies suitable patient populations. Immunotherapy has also become a rapidly expanding treatment category in South Korea, particularly immune checkpoint inhibitors used for cancers such as melanoma, lung cancer, and gastric cancer. These therapies enhance the immune system’s ability to detect and eliminate cancer cells, offering improved survival outcomes for selected patients. Hormonal therapies remain essential in treating hormone-sensitive cancers such as breast and prostate cancer and are frequently used in combination with other treatments. Advanced therapies including antibody-drug conjugates and CAR-T cell therapies are gradually being introduced in specialized cancer centers for patients with resistant or advanced disease. Treatment decisions are typically guided by multidisciplinary tumor boards that evaluate tumor genetics, disease stage, and patient health conditions before determining the most appropriate therapy. The coexistence of conventional chemotherapy and innovative precision therapies reflects South Korea’s balanced approach to oncology care.

The demand for cancer drugs in South Korea is shaped by the prevalence of major cancer types and the complexity of treatment required for each condition. Gastric cancer has historically been one of the most common cancers in the country and continues to drive significant demand for chemotherapy and targeted therapies. Lung cancer also represents a major oncology segment, particularly non-small cell lung cancer where targeted therapies and immunotherapies are widely used following molecular testing for specific genetic mutations. Colorectal cancer is another significant indication and is typically treated using a combination of chemotherapy and targeted biologic drugs. Breast cancer remains one of the most commonly diagnosed cancers among women in South Korea and is managed with a range of therapies including chemotherapy, hormonal treatments, targeted drugs, and immunotherapies depending on tumor subtype. Prostate cancer represents a growing treatment segment among men and is primarily treated with hormonal therapy, although chemotherapy and targeted drugs may be used for advanced disease. Hematologic malignancies such as leukemia, lymphoma, and multiple myeloma require specialized treatment approaches involving biologics, immunotherapies, and cellular therapies administered in advanced cancer centers. Other cancers including liver, pancreatic, ovarian, bladder, thyroid, brain, and skin cancers also contribute to overall oncology drug demand. National cancer screening programs and early detection initiatives further influence treatment patterns by identifying cancers at earlier stages when therapies are more effective.

Cancer drugs in South Korea are administered primarily through injectable and oral routes, both of which play essential roles in treatment delivery. Injectable therapies dominate chemotherapy, immunotherapy, and many biologic treatments and are typically administered in hospital oncology departments or specialized infusion units. These facilities provide controlled environments where healthcare professionals can monitor patients during treatment and manage potential side effects associated with complex drug regimens. Major hospitals maintain dedicated chemotherapy preparation units staffed with oncology pharmacists and nurses responsible for compounding and administering intravenous medications safely. Oral therapies have become increasingly important with the introduction of targeted small-molecule inhibitors and hormonal treatments that can be taken at home. These medications allow patients to continue treatment outside hospital settings, improving convenience and reducing the burden of frequent hospital visits. However, oral therapies require careful monitoring to ensure adherence and to manage potential adverse effects. Physicians and pharmacists often collaborate to provide patient education and follow-up care. The ability to combine injectable and oral therapies allows clinicians to design personalized treatment strategies tailored to the patient’s cancer type, disease stage, and overall health condition. Injectable therapies remain critical for aggressive cancers requiring intensive treatment protocols, while oral medications are commonly used for maintenance therapy and long-term disease management.



The distribution of cancer drugs in South Korea is supported by an integrated pharmaceutical supply chain involving hospital pharmacies, retail pharmacies, and pharmaceutical wholesalers. Hospital pharmacies play a central role in managing injectable oncology drugs such as chemotherapy agents, biologics, and immunotherapies. These pharmacies operate within hospitals and cancer treatment centers where pharmacists prepare medications under strict sterile conditions and ensure accurate dosing. Large tertiary hospitals and specialized cancer institutes often maintain dedicated oncology pharmacy departments capable of handling complex biologic therapies and high-value drugs. Retail pharmacies are primarily responsible for dispensing oral cancer medications and supportive treatments used to manage side effects associated with therapy. Pharmacists provide counseling and help monitor patient adherence to long-term treatment regimens. Pharmaceutical wholesalers and logistics companies ensure efficient distribution of oncology drugs across healthcare facilities while maintaining cold-chain conditions required for temperature-sensitive biologic products. Electronic prescription systems and integrated hospital networks further streamline the distribution process by improving coordination between physicians, hospitals, and pharmacies. The combination of hospital-based drug preparation, retail pharmacy services, and advanced logistics infrastructure ensures reliable access to both conventional chemotherapy medicines and innovative targeted therapies. This structured distribution framework supports efficient delivery of oncology treatments while maintaining strict safety and quality standards throughout the supply chain.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Other Treatment Types
By Indication
• Breast Cancer
• Lung Cancer (Non-Small Cell Lung Cancer and Small Cell Lung Cancer)
• Colorectal Cancer
• Prostate Cancer
• Blood Cancers (Leukemia, Lymphoma, Multiple Myeloma))
• cervical cancer
• Stomach/ Gastric Cancer
• Others (Liver Cancer ,Kidney Cancer (Renal Cell Carcinoma) , ovarian Cancer, Bladder Cancer, Skin Cancer, Brain tumor, Thyroid Cancer )
By Route of Administration
• Oral
• Injectable
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies / Drug Stores
• Online Pharmacies